financetom
Business
financetom
/
Business
/
What's Going On With Kenvue Stock Tuesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Kenvue Stock Tuesday?
Sep 23, 2025 9:09 AM

Kenvue Inc. ( KVUE ) shares are trading higher Tuesday despite President Donald Trump saying the Food and Drug Administration will notify physicians that use of acetaminophen or Tylenol during pregnancy could be associated with increase risk of autism.

What To Know: According to CNN, Trump said the FDA will recommend that pregnant women limit Tylenol use unless medically necessary, such as to treat fever. He described the risk of autism as "very increased," though the FDA said that while some studies have shown an association, "a causal relationship has not been established."

Health officials emphasized that untreated fever during pregnancy can pose serious risks, including miscarriage, birth defects and high blood pressure. Acetaminophen is widely considered the safest over-the-counter pain and fever relief option for pregnant people, with alternatives like ibuprofen and aspirin linked to higher complication risks.

Kenvue ( KVUE ) strongly disagreed with the claims, saying acetaminophen remains the safest pain reliever for pregnant women when used as directed. The company warned that discouraging its use could leave expectant mothers choosing between enduring potentially harmful fever and pain or turning to riskier alternatives.

The FDA also announced it will begin changing acetaminophen safety labels and issue guidance letters to physicians. Meanwhile, Health and Human Services Secretary Robert F. Kennedy Jr. said the agency will launch a national campaign encouraging clinicians to prescribe the lowest effective dose for the shortest duration necessary during pregnancy.

See Also: Ray Dalio Warns Of ‘Very, Very Dark Times,’ Says Learning To ‘Diversify My Bets’ Was The Key To Success: ‘A Smart Rabbit Has Three Holes’

KVUE Price Action: At the time of writing, Kenvue ( KVUE ) shares are trading 3.21% higher at $17.52, according to data from Benzinga Pro.

Image via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study
Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study
Aug 26, 2025
07:54 AM EDT, 08/26/2025 (MT Newswires) -- Marker Therapeutics ( MRKR ) said Tuesday its investigational therapy MT-601 achieved a 66% objective response rate in patients with relapsed non-Hodgkin lymphoma, and 50% showed a complete response. In the phase 1 study, eight out of 12 non-Hodgkin lymphoma patients responded to treatment, including six with complete responses, Marker Therapeutics ( MRKR...
MCF Energy Increased Financing To $1.2 Million
MCF Energy Increased Financing To $1.2 Million
Aug 26, 2025
07:55 AM EDT, 08/26/2025 (MT Newswires) -- MCF Energy ( MCFNF ) overnight Monday increased its previously announced non-brokered financing from $500,000 to $1,200,000. A statement noted the Offering will consist of 24 million units at a price of $0.05 per Unit. Each Unit will consist of one common share and one full common share purchase warrant with each warrant...
Market Chatter: Stellantis Axes First Level 3 Advanced Driver-Assistance Program
Market Chatter: Stellantis Axes First Level 3 Advanced Driver-Assistance Program
Aug 26, 2025
07:55 AM EDT, 08/26/2025 (MT Newswires) -- Stellantis ( STLA ) has axed its first Level 3 advanced driver-assistance program due to high costs, technology issues, and concerns over market viability, Reuters reported Tuesday, citing three sources familiar with the matter. According to Reuters, a Stellantis ( STLA ) spokesperson said the L3 technology that was announced in February has...
Regeneron Says Cemdisiran Monotherapy Meets Primary, Key Secondary Endpoints in Late-Stage Trial in Generalized Myasthenia Gravis Patients
Regeneron Says Cemdisiran Monotherapy Meets Primary, Key Secondary Endpoints in Late-Stage Trial in Generalized Myasthenia Gravis Patients
Aug 26, 2025
07:54 AM EDT, 08/26/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Tuesday that its investigational cemdisiran monotherapy met the primary and key secondary endpoints in a late-stage trial in adults with generalized myasthenia gravis. The company said Cemdisiran monotherapy showed a 2.3-point placebo-adjusted improvement in MG-ADL total score. Detailed results from the trial will be presented at an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved